The efficacy and safety of curcumin for pain relief in chronic kidney disease patients with knee osteoarthritis

The efficacy and safety of curcumin for pain relief in chronic kidney disease patients with knee osteoarthritis.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20191106006

Enrollment

Unknown

Registered

2019-11-06

Start date

2019-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

&#45

Interventions

500 mg (2tab) oral 4times per day,500 mg (2tab) oral 4times per day

Experimental Drug,Placebo Comparator Drug

curcumin,placebo

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Over 18 years old 2. CKD phase 3 - 4 3. Was diagnosed with osteoarthritis At the knee joint according to the Altman criteria and can match Kellgren-Lawrence grade 2 - 3 and have pain.

Exclusion criteria

Exclusion criteria: 1. pregnant 2. Underlying cirrhosis, hepatitis, bile duct disease or disease, cancer 3. Acute kidney injury, myocardial infartion 4. Curcumin allergy 5. Have a history of curcumin Or supplements that contain curcumin. Herbs or dietary supplements that reduce pain during the 2 months before the study. 6. Have a history of chondroitin sulfate, glucosamine, intraarticular hyaluron during the 2 months before the study.

Design outcomes

Primary

Measure	Time frame
pain 12, 24 weeks WOMAC pain subscale ,Quality of life 12, 24 weeks EQ5D5L,anxiety 12, 24 weeks Hospital anxiety and depression	—

Secondary

Measure	Time frame
side effect 12, 24 weeks physical examination	—

Countries

THAILAND

Contacts

Public Contactsupattra uppanisakorn

clinical research center

poohsupattra@gmail.com+66856781034

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026